Indaptus Therapeutics, Inc. (NASDAQ:INDP) Short Interest Update

Indaptus Therapeutics, Inc. (NASDAQ:INDP) was the recipient of a significant growth in short interest in February. As of February 15th, there was short interest totalling 78,500 shares, a growth of 102.8% from the January 31st total of 38,700 shares. Based on an average daily trading volume, of 25,400 shares, the short-interest ratio is presently 3.1 days. Currently, 0.7% of the company’s stock are sold short.

Indaptus Therapeutics Trading Up 6.8 %

Shares of INDP traded up $0.05 during trading hours on Friday, reaching $0.84. 4,970 shares of the stock traded hands, compared to its average volume of 60,980. The stock has a fifty day simple moving average of $0.87 and a 200 day simple moving average of $1.14. Indaptus Therapeutics has a 52 week low of $0.70 and a 52 week high of $3.10. The company has a market cap of $11.85 million, a price-to-earnings ratio of -0.49 and a beta of 1.46.

Analyst Upgrades and Downgrades

Separately, Maxim Group dropped their price objective on shares of Indaptus Therapeutics from $8.00 to $5.00 and set a “buy” rating on the stock in a research note on Wednesday, November 13th.

Indaptus Therapeutics Company Profile

Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.